Abstract
The effect of the anticonvulsant gabapentin on neuropathic pain was studied in six male patients with Fabry disease, aged 15-45 years. After 4 weeks of treatment, pain, as measured using the Brief Pain Inventory, was decreased compared with baseline. Treatment was generally well tolerated. This study indicates that gabapentin should be considered as a treatment option for the neuropathic pain of Fabry disease.
MeSH terms
-
Acetates / adverse effects
-
Acetates / therapeutic use*
-
Adolescent
-
Adult
-
Amines*
-
Anticonvulsants / adverse effects
-
Anticonvulsants / therapeutic use*
-
Cyclohexanecarboxylic Acids*
-
Fabry Disease / complications*
-
Gabapentin
-
Humans
-
Male
-
Neuralgia / drug therapy*
-
Neuralgia / etiology*
-
Neuralgia / physiopathology
-
Pain Measurement
-
Treatment Outcome
-
gamma-Aminobutyric Acid*
Substances
-
Acetates
-
Amines
-
Anticonvulsants
-
Cyclohexanecarboxylic Acids
-
gamma-Aminobutyric Acid
-
Gabapentin